Nurix Therapeutics (NRIX)
(Delayed Data from NSDQ)
$11.04 USD
-0.22 (-1.95%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $11.02 -0.02 (-0.18%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NRIX 11.04 -0.22(-1.95%)
Will NRIX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NRIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NRIX
Nurix Therapeutics, Inc. (NRIX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know
NRIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?
Beyond Air, Inc. (XAIR) Reports Q4 Loss, Misses Revenue Estimates
Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last?
Other News for NRIX
Insider Sell Alert: Houte Van Sells Shares of Nurix Therapeutics Inc (NRIX)
Oppenheimer Reiterates Outperform Rating for Nurix Therapeutics (NRIX) | NRIX Stock News
Oppenheimer Adjusts Price Target for Nurix Therapeutics (NRIX)
Nurix Therapeutics price target lowered by $2 at Oppenheimer, here's why
6 Analysts Assess Nurix Therapeutics: What You Need To Know